Merck & Co., Inc. - Product Pipeline Review - 2015

  • ID: 3266289
  • Company Profile
  • 370 pages
  • Global Markets Direct
  • Merck & Co., Inc.
1 of 4
Merck & Co., Inc. - Product Pipeline Review - 2015

Summary

This, ‘Merck & Co., Inc. - Product Pipeline Review - 2015’, provides an overview of the Merck & Co., Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Merck & Co., Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Merck & Co., Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Merck & Co., Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Merck & Co., Inc.’s pipeline products

Reasons to buy

- Evaluate Merck & Co., Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Merck & Co., Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Merck & Co., Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Merck & Co., Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Merck & Co., Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Merck & Co., Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables
List of Figures
Merck & Co., Inc. Snapshot
Merck & Co., Inc. Overview
Key Information
Key Facts
Merck & Co., Inc. - Research and Development Overview
Key Therapeutic Areas
Merck & Co., Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Pipeline Products - Out-Licensed Products
Merck & Co., Inc. - Pipeline Products Glance
Merck & Co., Inc. - Late Stage Pipeline Products
Merck & Co., Inc. - Clinical Stage Pipeline Products
Merck & Co., Inc. - Early Stage Pipeline Products
Merck & Co., Inc. - Unknown Stage Pipeline Products
Merck & Co., Inc. - Drug Profiles
(ceftolozane sulfate + tazobactam sodium)
(lamivudine + raltegravir potassium)
diquafosol tetrasodium
human papillomavirus (9-valent) vaccine
omarigliptin
pembrolizumab
sugammadex sodium
tedizolid phosphate
corifollitropin alfa
(actoxumab + bezlotoxumab)
(doravirine + lamivudine + tenofovir disoproxil fumarate)
(ertugliflozin + metformin)
(ertugliflozin + sitagliptin)
(etoricoxib + tizanidine)
(grazoprevir + elbasvir)
actoxumab
anacetrapib
aprepitant
asenapine maleate
bevenopran
bezlotoxumab
desloratadine
doravirine
fidaxomicin
insulin glargine
letermovir
MK-8237
MK-8931
odanacatib
posaconazole
rituximab biosimilar
solithromycin
surotomycin
V-212
V-920
vibegron
vorinostat
BQ-123
dalotuzumab
grazoprevir
lomerizine
lonafarnib
mirtazapine ODT
MK-1029
MK-2206
MK-2206 + selumetinib sulfate
MK-7622
MK-8342B
MK-8628
narlaprevir
relebactam
samatasvir
temozolomide
V-114
MK-3682
CB-618
MK-0752
MK-1075
MK-2048
MK-2248
MK-2640
MK-4166
MK-7680
MK-8150
MK-8189
MK-8242
MK-8291
MK-8408
MK-8507
MK-8521
MK-8591
MK-8666
MK-8723
MK-8876
Monoclonal Antibody for Autoimmune Diseases
NB-1008
SCH-772984
Small Molecule 1 for Human Cytomegalovirus Infection
Small Molecule 2 for Human Cytomegalovirus Infection
V-160
V-180
BNC-375
CB-027
chikungunya vaccine
DORA-12
Drug to Inhibit 11Beta-HSD1 for Hypertension
Drugs to Inhibit CYP11B2 for Cardiovascular Diseases
ETP-142
GP-4
GRA-1
J8-CRM197
M-867
mDX-400
MK-4256
MK-8745
MK-8825
MK-8970
Monoclonal Antibodies to Inhibit PCSK9 for Hypercholesterolemia
MRK-003
Oligonucleotides for Viral Infections
OTX-009
Proteins for Cancer, Autoimmune and Inflammatory diseases
PTC-512
PTC-725
PTC-971
respiratory syncytial virus vaccine
SCH-412348
SCH-546738
Small Molecule 3 for Human Cytomegalovirus Infection
Small Molecule to Agonize Glucocorticoid Receptor for Respiratory Disorders
Small Molecule to Inhibit JAK2 for Myeloproliferative Disorder
Small Molecule to Inhibit Kinesin Spindle Protein for Cancer
Small Molecule to Inhibit PLK1 for Cancer
Small Molecules for Atherosclerosis
Small Molecules to Agonize M1 for Alzheimer’s Disease
Small Molecules to Agonize TLR7/8/9 for Cancer, Alzheimer's Disease and Infectious Disease
Small Molecules to Block Cav2.2 Channel for Chronic Pain
Small Molecules to Inhibit DHFR for Septicaemia
Small Molecules to Inhibit NS5B Polymerase for Hepatitis C
Small Molecules to Inhibit Prolyl Hydroxylase for Anemia
THPP-1
TROX-1
XEN-445
XL-499
Biosimilars for Undisclosed Indication
Drug to Target GPCR for Undisclosed Indication
hepatitis C vaccine
Kibdelomycin A
Monoclonal Antibodies for Undisclosed Indication
Monoclonal Antibody for Cancer
Monoclonal Antibody for Neurology
SCH-722984
Small Molecules for Undisclosed Indication
Small Molecules to Inhibit CGRP Receptor for Migraine
Small Molecules to Inhibit DGAT1 for Undisclosed Indication
Small Molecules to Inhibit Renin for Undisclosed Indication
Small Molecules to Activate sGC for Cardiovascular Disease
Merck & Co., Inc. - Pipeline Analysis
Merck & Co., Inc. - Pipeline Products by Target
Merck & Co., Inc. - Pipeline Products by Route of Administration
Merck & Co., Inc. - Pipeline Products by Molecule Type
Merck & Co., Inc. - Pipeline Products by Mechanism of Action
Merck & Co., Inc. - Recent Pipeline Updates
Merck & Co., Inc. - Dormant Projects
Merck & Co., Inc. - Dormant Projects
Merck & Co., Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Merck & Co., Inc. - Company Statement
Merck & Co., Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Merck & Co., Inc., Key Information
Merck & Co., Inc., Key Facts
Merck & Co., Inc. - Pipeline by Indication, 2015
Merck & Co., Inc. - Pipeline by Stage of Development, 2015
Merck & Co., Inc. - Monotherapy Products in Pipeline, 2015
Merck & Co., Inc. - Combination Treatment Modalities in Pipeline, 2015
Merck & Co., Inc. - Partnered Products in Pipeline, 2015
Merck & Co., Inc. - Partnered Products/ Combination Treatment Modalities, 2015
Merck & Co., Inc. - Out-Licensed Products in Pipeline, 2015
Merck & Co., Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015
Merck & Co., Inc. - Pre-Registration, 2015
Merck & Co., Inc. - Filing rejected/Withdrawn, 2015
Merck & Co., Inc. - Phase III, 2015
Merck & Co., Inc. - Phase II, 2015
Merck & Co., Inc. - Phase I, 2015
Merck & Co., Inc. - Preclinical, 2015
Merck & Co., Inc. - Discovery, 2015
Merck & Co., Inc. - Unknown, 2015
Merck & Co., Inc. - Pipeline by Target, 2015
Merck & Co., Inc. - Pipeline by Route of Administration, 2015
Merck & Co., Inc. - Pipeline by Molecule Type, 2015
Merck & Co., Inc. - Pipeline Products by Mechanism of Action, 2015
Merck & Co., Inc. - Recent Pipeline Updates, 2015
Merck & Co., Inc. - Dormant Developmental Projects,2015
Merck & Co., Inc. - Discontinued Pipeline Products, 2015
Merck & Co., Inc., Subsidiaries

List of Figures
Merck & Co., Inc. - Pipeline by Top 10 Indication, 2015
Merck & Co., Inc. - Pipeline by Stage of Development, 2015
Merck & Co., Inc. - Monotherapy Products in Pipeline, 2015
Merck & Co., Inc. - Combination Treatment Modalities in Pipeline, 2015
Merck & Co., Inc. - Partnered Products in Pipeline, 2015
Merck & Co., Inc. - Out-Licensed Products in Pipeline, 2015
Merck & Co., Inc. - Pipeline by Top 10 Target, 2015
Merck & Co., Inc. - Pipeline by Top 10 Route of Administration, 2015
Merck & Co., Inc. - Pipeline by Top 10 Molecule Type, 2015
Merck & Co., Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll